Thermo Fisher Scientific Debt/Equity Ratio 2010-2025 | TMO

Thermo Fisher Scientific debt/equity ratio for the quarter ending March 31, 2025 was 0.64.

  • Thermo Fisher Scientific average debt/equity ratio for 2024 was 0.64, a 5.88% decline from 2023.
  • Thermo Fisher Scientific average debt/equity ratio for 2023 was 0.68, a 1.45% decline from 2022.
  • Thermo Fisher Scientific average debt/equity ratio for 2022 was 0.69, a 15% decline from 2021.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.

Quarterly Chart

Click on chart icon to view chart
Click on table icon to view table

Annual

Click on chart icon to view chart
Click on table icon to view table
Related Stocks
Company NameMarket
Cap
Intuitive Surgical (ISRG)$171.9B
Alcon (ALC)$45.6B
Edwards Lifesciences (EW)$42B
IDEXX Laboratories (IDXX)$33.3B
DexCom (DXCM)$26.9B
IQVIA Holdings (IQV)$25.4B
STERIS (STE)$21.8B
Mettler-Toledo (MTD)$20.9B
Waters (WAT)$19.1B
SONOVA HOLDING (SONVY)$17.3B
Fresenius Medical Care AG KGaA (FMS)$13.9B
Hologic (HOLX)$12.9B
Sysmex ADR (SSMXY)$11.8B
Penumbra (PEN)$10.7B
Globus Medical (GMED)$9.8B
Masimo (MASI)$8.2B
Teleflex (TFX)$6B
Glaukos (GKOS)$5.2B
Integer Holdings (ITGR)$4.1B
TransMedics (TMDX)$3B
PROCEPT BioRobotics (PRCT)$2.9B
Veracyte (VCYT)$2.4B
Nihon Kohden (NHNKY)$2.1B
LivaNova (LIVN)$1.9B
Elekta AB (EKTAY)$1.9B
Alphatec Holdings (ATEC)$1.5B
Integra LifeSciences Holdings (IART)$1.2B
Pulse Biosciences (PLSE)$1.2B
Tandem Diabetes Care (TNDM)$1.1B
Paragon 28 (FNA)$1.1B